Glycated Lysine Residues: A Marker for Non-Enzymatic Protein Glycation in Age-Related Diseases

Nonenzymatic glycosylation or glycation of macromolecules, especially proteins leading to their oxidation, play an important role in diseases. Glycation of proteins primarily results in the formation of an early stage and stable Amadori-lysine product which undergo further irreversible chemical reactions to form advanced glycation endproducts (AGEs). This review focuses these products in lysine rich proteins such as collagen and human serum albumin for their role in aging and age-related diseases. Antigenic characteristics of glycated lysine residues in proteins together with the presence of serum autoantibodies to the glycated lysine products and lysine-rich proteins in diabetes and arthritis patients indicates that these modified lysine residues may be a novel biomarker for protein glycation in aging and age-related diseases.

[1]  L. Wilhelmsen,et al.  Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. , 2001, Clinical science.

[2]  P. Riederer,et al.  Amino acid specificity of glycation and protein–AGE crosslinking reactivities determined with a dipeptide SPOT library , 1999, Nature Biotechnology.

[3]  J. Liang.  Circular dichroism of the non-enzymatic browning products of poly-L-lysine and albumin. , 1990, International journal of biological macromolecules.

[4]  R. Nagaraj,et al.  Plasma Protein Pentosidine and Carboxymethyllysine, Biomarkers for Age-related Macular Degeneration* , 2009, Molecular & Cellular Proteomics.

[5]  Toshio Miyata,et al.  Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics , 2010, Amino Acids.

[6]  P. Lipsky,et al.  Autoantibodies as predictors of disease. , 2001, The Journal of clinical investigation.

[7]  Sven Bulterijs,et al.  Characteristics, formation, and pathophysiology of glucosepane: a major protein cross-link. , 2009, Rejuvenation research.

[8]  H. Parving,et al.  Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. , 1999, Diabetes.

[9]  M. Newkirk,et al.  A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. , 1998, British journal of rheumatology.

[10]  C. Gerhardinger,et al.  Pyrolysis/gas chromatography/mass spectrometry in the analysis of glycated poly-L-lysine , 1992 .

[11]  Su-Yen Goh,et al.  The role of advanced glycation end products in progression and complications of diabetes , 2008 .

[12]  V. J. Stevens,et al.  Diabetic cataract formation: potential role of glycosylation of lens crystallins. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[13]  N. Morgan,et al.  Islet glutamic acid decarboxylase modified by reactive oxygen species is recognized by antibodies from patients with type 1 diabetes mellitus , 2001, Clinical and experimental immunology.

[14]  C. Valeri,et al.  Autoantibodies in Type 1 diabetes. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[15]  T. Lyons,et al.  Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. , 1991, Biochemistry.

[16]  Paul J Thornalley,et al.  Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment , 2005, Journal of neurochemistry.

[17]  Seema Sharma,et al.  Non-enzymatic glycosylation of immunoglobulins in diabetic nephropathy. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[18]  B. Kristal,et al.  An emerging hypothesis: synergistic induction of aging by free radicals and Maillard reactions. , 1992, Journal of gerontology.

[19]  A. Acharya,et al.  Amadori rearrangement of glyceraldehyde-hemoglobin Schiff base adducts. A new procedure for the determination of ketoamine adducts in proteins. , 1980, The Journal of biological chemistry.

[20]  N. Chaturvedi,et al.  Amadori‐albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients , 2002, European journal of clinical investigation.

[21]  E. Gravallese,et al.  Nonenzymatic Glycosylation of Erythrocyte Membrane Proteins , 1980 .

[22]  C. Palumbo,et al.  A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth. , 2009, Cancer letters.

[23]  Paul J Thornalley,et al.  Therapy: Vitamin B6, B9 and B12 in diabetic nephropathy—beware , 2010, Nature Reviews Endocrinology.

[24]  J. Miller,et al.  Nonenzymatic glycosylation of erythrocyte membrane proteins. Relevance to diabetes. , 1980, The Journal of clinical investigation.

[25]  E. Schleicher,et al.  Maillard Products as Biomarkers in Cancer , 2008, Annals of the New York Academy of Sciences.

[26]  G. Wondrak,et al.  Histone carbonylation in vivo and in vitro. , 2000, The Biochemical journal.

[27]  F. Collard,et al.  The Role of the Amadori Product in the Complications of Diabetes , 2008, Annals of the New York Academy of Sciences.

[28]  S. Z. Bathaie,et al.  The improvement effect of L‐Lys as a chemical chaperone on STZ‐induced diabetic rats, protein structure and function , 2008, Diabetes/metabolism research and reviews.

[29]  R. Hoffmann,et al.  Site‐specific synthesis of Amadori‐modified peptides on solid phase , 2006, Journal of peptide science : an official publication of the European Peptide Society.

[30]  P. D. de Groot,et al.  Glycation Induces Formation of Amyloid Cross-β Structure in Albumin* , 2003, Journal of Biological Chemistry.

[31]  D A Armbruster,et al.  Fructosamine: structure, analysis, and clinical usefulness. , 1987, Clinical chemistry.

[32]  S. Mende,et al.  Model Studies on Protein Glycation , 2008, Annals of the New York Academy of Sciences.

[33]  T. Sun,et al.  Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant alpha-crystallins. , 1999, Current eye research.

[34]  R. H. Scofield,et al.  Autoimmunity and oxidatively modified autoantigens. , 2008, Autoimmunity reviews.

[35]  M. Weksler,et al.  Do age-associated changes in ‘physiologic’ autoantibodies contribute to infection, atherosclerosis, and Alzheimer's disease? , 2002, Experimental Gerontology.

[36]  K. Nair,et al.  Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. , 2005, Diabetes care.

[37]  Asif Ali,et al.  Preferential recognition of Amadori-rich lysine residues by serum antibodies in diabetes mellitus: role of protein glycation in the disease process. , 2009, Human immunology.

[38]  M. Cohen,et al.  Amelioration of diabetic nephropathy by treatment with monoclonal antibodies against glycated albumin. , 1994, Kidney international.

[39]  C. Schalkwijk,et al.  Advanced Glycation End Products in Human Cancer Tissues: Detection of Nε‐(Carboxymethyl)lysine and Argpyrimidine , 2005, Annals of the New York Academy of Sciences.

[40]  M. P. Cohen,et al.  Rate of Formation of Glycated Albumin Revisited and Clinical Implications , 2010 .

[41]  S. Vannucci,et al.  Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. , 2005, Glycobiology.

[42]  Anne Dawnay,et al.  Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. , 2003, The Biochemical journal.

[43]  Keji Chen,et al.  The essential mechanisms of aging: Irreparable damage accumulation of biochemical side-reactions , 2005, Experimental Gerontology.

[44]  H. El-Gabalawy,et al.  Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis , 2003, Arthritis research & therapy.

[45]  P. Gallop,et al.  Structural heterogeneity of human hemoglobin A due to nonenzymatic glycosylation. , 1979, The Journal of biological chemistry.

[46]  Jack Liang,et al.  Conformational Study of Nɛ-(carboxymethyl)lysine Adducts of Recombinant γC-crystallin , 2001 .

[47]  H. Saya,et al.  Study of autoantibodies against advanced glycation endproducts of the Maillard reaction , 2001 .

[48]  A. Gugliucci,et al.  Caffeic and chlorogenic acids in Ilex paraguariensis extracts are the main inhibitors of AGE generation by methylglyoxal in model proteins. , 2009, Fitoterapia.

[49]  J. Baynes,et al.  Glycation, Glycoxidation, and Cross-Linking of Collagen by Glucose: Kinetics, Mechanisms, and Inhibition of Late Stages of the Maillard Reaction , 1994, Diabetes.

[50]  Cheolju Lee,et al.  Protein Glycation , 2001, Annals of the New York Academy of Sciences.

[51]  J. Baynes,et al.  Glycation of amino groups in protein. Studies on the specificity of modification of RNase by glucose. , 1985, The Journal of biological chemistry.

[52]  A. Cerami,et al.  Protein glycation, diabetes, and aging. , 2001, Recent progress in hormone research.

[53]  N. Taniguchi,et al.  Immunological detection of glycated proteins in normal and streptozotocin-induced diabetic rats using anti hexitol-lysine IgG. , 1995, Biochimica et biophysica acta.

[54]  V. Monnier.  Nonenzymatic glycosylation, the Maillard reaction and the aging process. , 1990, Journal of gerontology.

[55]  S. Ogawa,et al.  Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[56]  H. Sano,et al.  Hydroxyl Radical Mediates Nϵ-(Carboxymethyl)lysine Formation from Amadori Product , 1997 .

[57]  E. Schleicher,et al.  Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.

[58]  Tanuja Kosuri,et al.  Immunochemical detection of glycated lens crystallins and their circulating autoantibodies in human serum during aging , 2008, Molecular vision.

[59]  B. Friguet,et al.  Increased level of glycoxidation product N(epsilon)-(carboxymethyl)lysine in rat serum and urine proteins with aging: link with glycoxidative damage accumulation in kidney. , 2003, Archives of biochemistry and biophysics.

[60]  T. Arendt,et al.  Immunochemical crossreactivity of antibodies specific for “advanced glycation endproducts” with “advanced lipoxidation endproducts” , 2005, Neurobiology of Aging.

[61]  T. Miyata,et al.  Carbonyl Stress and Diabetic Complications , 2003, Clinical chemistry and laboratory medicine.

[62]  B. Ortwerth,et al.  2-Ammonio-6-(3-oxidopyridinium-1-yl)hexanoate (OP-lysine) Is a Newly Identified Advanced Glycation End Product in Cataractous and Aged Human Lenses* , 2004, Journal of Biological Chemistry.

[63]  S. Bandinelli,et al.  Plasma Carboxymethyl‐Lysine, an Advanced Glycation End Product, and All‐Cause and Cardiovascular Disease Mortality in Older Community‐Dwelling Adults , 2009, Journal of the American Geriatrics Society.

[64]  Zafar Rasheed,et al.  Reactive oxygen species damaged human serum albumin in patients with type 1 diabetes mellitus: biochemical and immunological studies. , 2006, Life sciences.

[65]  I. Mook‐Jung,et al.  Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice. , 2007, Biochemical and biophysical research communications.

[66]  H. Bunn,et al.  Nonenzymatic glycosylation of human serum albumin alters its conformation and function. , 1984, The Journal of biological chemistry.

[67]  D. Cervantes-Laurean,et al.  Nuclear proteasome activation and degradation of carboxymethylated histones in human keratinocytes following glyoxal treatment. , 2005, Free radical biology & medicine.

[68]  M. Pischetsrieder,et al.  Aged garlic extract and S-allyl cysteine prevent formation of advanced glycation endproducts. , 2007, European journal of pharmacology.

[69]  M. Nangaku,et al.  Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. , 1998, Biochemical and biophysical research communications.

[70]  V. Monnier,et al.  Cross‐Linking of the Extracellular Matrix by the Maillard Reaction in Aging and Diabetes: An Update on “a Puzzle Nearing Resolution” , 2005, Annals of the New York Academy of Sciences.

[71]  N. Turk,et al.  Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[72]  S. Horiuchi,et al.  Autoantibody against N(epsilon)-(carboxymethyl)lysine: an advanced glycation end product of the Maillard reaction. , 1999, Diabetes.

[73]  柴山 利恵.  Autoantibody against Nε-(carboxymethyl)lysine an advanced glycation end product of the Maillard reaction , 2000 .

[74]  H. Kaneshige.  Nonenzymatic Glycosylation of Serum IgG and Its Effect on Antibody Activity in Patients With Diabetes Mellitus , 1987, Diabetes.

[75]  O. Wieland,et al.  Preparation and biological properties of glycosylated insulin , 1979, FEBS letters.

[76]  K. Kushida,et al.  Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis. , 1998, The Journal of rheumatology.

[77]  Z. Rasheed,et al.  Advanced Glycation End Products (AGEs) Damaged IgG, a Target for Circulating Autoantibodies in Patients with Type 1 Diabetes Mellitus , 2009 .

[78]  B. S. Rao,et al.  Immunochemical detection of glycated beta- and gamma-crystallins in lens and their circulating autoantibodies (IgG) in streptozocin induced diabetic rat. , 2006, Molecular vision.

[79]  Moinuddin,et al.  Characterization of hydroxyl radical modified GAD65: A potential autoantigen in type 1 diabetes , 2009, Autoimmunity.